Mon panier

Biotinylated Human GIPR Protein, His,Avitag™ (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
GIR-H82E3-25ug
$450.00
GIR-H82E3-200ug
$1880.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    PGQTL2

  • Source

    Biotinylated Human GIPR Protein, His,Avitag (GIR-H82E3) is expressed from human 293 cells (HEK293). It contains AA Gly 26 - Gln 138 (Accession # P48546-1).

    Predicted N-terminus: Gly 26

    Request for sequence
  • Molecular Characterization

    GIPR Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 16.6 kDa. The protein migrates as 21-31 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    GIPR SDS-PAGE

    Biotinylated Human GIPR Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    GIPR SEC-MALS

    The purity of Biotinylated Human GIPR Protein, His,Avitag (Cat. No. GIR-H82E3) is more than 85% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     GIPR ELISA

    Immobilized Biotinylated Human GIPR Protein, His,Avitag (Cat. No. GIR-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-GIPR Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     GIPR SPR

    Monoclonal Anti-GIPR Antibody, Human IgG1 captured on Protein A Chip can bind Biotinylated Human GIPR Protein, His,Avitag (Cat. No. GIR-H82E3) with an affinity constant of 105 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  GIPR SPR

    Biotinylated Human GIPR Protein, His,Avitag (Cat. No. GIR-H82E3) immobilized on SA Chip can bind Human GIP Protein with an affinity constant of 44.6 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

This gene encodes a G-protein coupled receptor for gastric inhibitory polypeptide (GIP), which was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release in the presence of elevated glucose. Mice lacking this gene exhibit higher blood glucose levels with impaired initial insulin response after oral glucose load. Defect in this gene thus may contribute to the pathogenesis of diabetes. [provided by RefSeq, Oct 2011]

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte